In the GRADE trial of 1,739 type 2 diabetes patients, liraglutide (GLP-1 agonist) reduced diabetes-related emotional distress compared to other treatments, and basal insulin did not increase distress — challenging common assumptions about treatment burden.
Liraglutide reduced diabetes distress (P=0.008)GLP-1 agonist showed lower diabetes distress than glimepiride or sitagliptin at 1 year, with sustained interpersonal distress benefits over 3 years
What the researchers found
In 1,739 GRADE trial participants randomized to add insulin glargine, glimepiride, liraglutide, or sitagliptin to metformin:
At 1 year:
- All treatments reduced diabetes distress (-0.24, P < 0.0001) and depressive symptoms (-0.67, P < 0.0001)
- Insulin glargine showed lower diabetes distress than other groups combined (-0.10, P = 0.002)
- Liraglutide showed lower diabetes distress than glimepiride or sitagliptin (-0.10, P = 0.008)
Over 3-year follow-up:
- No significant differences in total diabetes distress between groups
- Interpersonal diabetes distress remained lower for liraglutide
- No significant differences in depressive symptoms between any groups
Key conclusion: Contrary to expectations, basal insulin did NOT increase emotional distress.
Why it matters
Fear of injections and concerns about treatment burden are major barriers to diabetes medication adherence. Many patients resist starting insulin or injectable GLP-1 drugs because they worry about the psychological impact. This large randomized trial provides reassuring evidence: injectable treatments didn't worsen emotional health, and liraglutide actually improved it. For clinicians, these findings can help overcome patient resistance to effective injectable therapies and support shared decision-making about treatment options.
How the study worked
Emotional Distress Substudy of the GRADE (Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study) trial. 1,739 adults with T2DM <10 years' duration on metformin monotherapy were randomized to add insulin glargine, glimepiride, liraglutide, or sitagliptin. Diabetes distress and depressive symptoms were assessed every 6 months for 3 years using validated instruments. Analyses compared groups at 1 year and over the full follow-up.
What this study cannot tell us
The emotional distress substudy enrolled 1,739 of the larger GRADE trial's participants, introducing potential selection bias. The -0.10 point differences, while statistically significant, are modest in clinical terms. The study population (mean age 58, majority non-Hispanic White) may not represent all T2DM patients. Depression was mild overall, so effects might differ in populations with higher baseline depression. Blinding was not possible due to the different administration routes, which could influence psychological outcomes.
How to read the evidence
This is a substudy of a large, well-designed randomized controlled trial (GRADE) — one of the most important diabetes comparative effectiveness studies. The randomized design, large sample, and long follow-up provide strong evidence. The open-label design (patients knew their treatment) is a limitation for psychological outcomes but unavoidable given the different drug types.
When this study was published
Published in 2024 in Diabetes Care, this is a recent and highly authoritative study from the GRADE trial, one of the landmark diabetes studies of the past decade.
The bigger picture
This study from the landmark GRADE trial adds an important psychological dimension to the diabetes treatment conversation. As GLP-1 agonists become more widely prescribed, understanding their effects on emotional wellbeing — not just metabolic markers — is increasingly important. The finding that liraglutide uniquely reduces interpersonal diabetes distress may relate to its weight loss benefits (less social stigma) or other quality-of-life improvements. This type of patient-centered outcome data is essential for truly comprehensive treatment evaluation.
Questions still open
- Would newer GLP-1RAs like semaglutide show even greater reductions in diabetes distress due to their greater weight loss effects?
- Is the interpersonal distress benefit of liraglutide related to weight loss and reduced diabetes stigma?
- Should emotional wellbeing outcomes be given more weight in diabetes treatment selection?
Common questions
Will starting insulin make me feel worse emotionally?
Why might liraglutide reduce emotional distress more than other diabetes drugs?
Read the original research
Differential Effects of Type 2 Diabetes Treatment Regimens on Diabetes Distress and Depressive Symptoms in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
Diabetes care, 47(4), 610-619
Citation
Gonzalez, Jeffrey S; Bebu, Ionut; Krause-Steinrauf, Heidi; Hoogendoorn, Claire J; Crespo-Ramos, Gladys; Presley, Caroline; Naik, Aanand D; Kuo, Shihchen; Johnson, Mary L; Wexler, Deborah; Crandall, Jill P; Bantle, Anne E; Arends, Valerie; Cherrington, Andrea L. (2024). Differential Effects of Type 2 Diabetes Treatment Regimens on Diabetes Distress and Depressive Symptoms in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).. Diabetes care, 47(4), 610-619. https://doi.org/10.2337/dc23-2459